COVID-19-associated optic neuritis – A case series and review of literature

Jossy, Ajax; Jacob, Ninan; Sarkar, Sandip; Gokhale, Tanmay; Kaliaperumal, Subashini; Deb, Amit Kumar

doi:10.4103/ijo.ijo_2235_21

Cited by 42 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several rare manifestations of COVID‐19 have been reported in the literature, with these manifestations including seizures and status epilepticus (Asadi‐Pooya et al, 2021), meningoencephalitis (Oosthuizen et al, 2021), Guillain–Barré syndrome (Toscano et al, 2020), acute necrotizing encephalopathy (Geng et al, 2023), and multisystem inflammatory syndrome in children (Whittaker et al, 2020). In addition, myositis (Saud et al, 2021), catatonia (Anvekar et al, 2022), vasculitis and arthritis (Batu et al, 2022), optic neuritis (Jossy et al, 2022), dermatological manifestations (Lipsker, 2020; Marraha et al, 2020), conjunctivitis (Danthuluri & Grant, 2020), and endocrine and metabolic complications (Esmaeilzadeh et al, 2022) have been observed. Some of these rare manifestations might be associated with a poor prognosis.…”

Section: Brief Review Of Coronavirus 2019mentioning

confidence: 99%

Effect and mechanism of quercetin or quercetin‐containing formulas against COVID‐19: From bench to bedside

Chen,

Huang,

Hsu

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has caused the global coronavirus disease 2019 (COVID‐19) pandemic since 2019. Immunopathogenesis and thromboembolic events are central to its pathogenesis. Quercetin exhibits several beneficial activities against COVID‐19, including antiviral, anti‐inflammatory, immunomodulatory, antioxidative, and antithrombotic effects. Although several reviews have been published, these reviews are incomplete from the viewpoint of translational medicine. The authors comprehensively evaluated the evidence of quercetin against COVID‐19, both basically and clinically, to apply quercetin and/or its derivatives in the future. The authors searched the PubMed, Embase, and the Cochrane Library databases without any restrictions. The search terms included COVID‐19, SARS‐CoV‐2, quercetin, antiviral, anti‐inflammatory, immunomodulatory, thrombosis, embolism, oxidative, and microbiota. The references of relevant articles were also reviewed. All authors independently screened and reviewed the quality of each included manuscript. The Cochrane Risk of Bias Tool, version 2 (RoB 2) was used to assess the quality of the included randomized controlled trials (RCTs). All selected studies were discussed monthly. The effectiveness of quercetin against COVID‐19 is not solid due to methodological flaws in the clinical trials. High‐quality studies are also required for quercetin‐containing traditional Chinese medicines. The low bioavailability and highly variable pharmacokinetics of quercetin hinder its clinical applications. Its positive impact on immunomodulation through reverting dysbiosis of gut microbiota still lacks robust evidence. Quercetin against COVID‐19 does not have tough clinical evidence. Strategies to improve its bioavailability and/or to develop its effective derivatives are needed. Well‐designed RCTs are also crucial to confirm their effectiveness in the future.

show abstract

Section: Brief Review Of Coronavirus 2019mentioning

confidence: 99%

Effect and mechanism of quercetin or quercetin‐containing formulas against COVID‐19: From bench to bedside

Chen,

Huang,

Hsu

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…In addition, because D-dimer and erythrocyte sedimentation rates (ESR) were the only laboratory parameters that were higher in these patients compared with controls, the authors concluded that ocular comorbidities could be related to systemic inflammation related to SARS-CoV-2 infection, particularly coagulation alterations. Jossy et al [ 84 ] described three patients who developed optic neuritis while recovering from COVID-19 infection. One was positive for serum antigens.…”

Section: Long-covid Neurological and Psychological Symptomsmentioning

confidence: 99%

Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches

Conti

Corbi

Sabbatino

et al. 2023

JPM

View full text Add to dashboard Cite

More than two years after the onset of the COVID-19 pandemic, healthcare providers are facing an emergency within an emergency, the so-called long COVID or post-COVID-19 syndrome (PCS). Patients diagnosed with PCS develop an extended range of persistent symptoms and/or complications from COVID-19. The risk factors and clinical manifestations are many and various. Advanced age, sex/gender, and pre-existing conditions certainly influence the pathogenesis and course of this syndrome. However, the absence of precise diagnostic and prognostic biomarkers may further complicate the clinical management of patients. This review aimed to summarize recent evidence on the factors influencing PCS, possible biomarkers, and therapeutic approaches. Older patients recovered approximately one month earlier than younger patients, with higher rates of symptoms. Fatigue during the acute phase of COVID-19 appears to be an important risk factor for symptom persistence. Female sex, older age, and active smoking are associated with a higher risk of developing PCS. The incidence of cognitive decline and the risk of death are higher in PCS patients than in controls. Complementary and alternative medicine appears to be associated with improvement in symptoms, particularly fatigue. The heterogeneous nature of post-COVID symptoms and the complexity of patients with PCS, who are often polytreated due to concomitant clinical conditions, suggest a holistic and integrated approach to provide useful guidance for the treatment and overall management of long COVID.

show abstract

“…Optic neuritis (ON) induced by COVID‐19 is a very rare manifestation that sometimes causes relapsing inflammatory optic neuropathy. Several studies have shown that patients with COVID‐19‐induced ON have a good visual recovery (Josy et al., 2022; Sawalha et al., 2020). However, these scattered reports do not give us a systematic understanding of first‐episode ON after COVID‐19.…”

Section: Figurementioning

confidence: 99%

Clinical features and prognosis in the first episode of optic neuritis with COVID‐19

Li,

Sun,

et al. 2023

Acta Ophthalmologica

View full text Add to dashboard Cite

Optic neuritis (ON) induced by COVID-19 is a very rare manifestation that sometimes causes relapsing inflammatory optic neuropathy. Several studies have shown that patients with COVID-19-induced ON have a good visual recovery (Josy et al., 2022; Sawalha et al., 2020). However, these scattered reports do not give us a systematic understanding of first-episode ON after COVID-19.We prospectively collected clinical data from 13 hospitalized patients diagnosed with post-COVID-19 ON. All of these patients experienced an initial attack, but none of them experienced a relapsing course of neuromyelitis optical spectrum disorders or myelin oligodendrocyte glycoprotein antibody-associated disease. We aimed to report the clinical features and prognosis of first-episode ON after COVID-19.In this study, the clinical records of hospitalized patients who were first diagnosed with post-COVID 19 ON between December 2022 and February 2023 were collected from department of neuro-ophthalmology of the People's Liberation Army General Hospital (PLAGH) in China. We analysed the clinical characteristics, examinations, treatments and prognosis of the ON patients. Informed consent was obtained from all patients. The study protocol was approved by the institutional review board of PLAGH (S2020-D09-01), and the study was performed in accordance with the Helsinki Declaration. Informed consent was obtained from all the patients.The diagnosis and treatment of ON were carried out according to The Optic Neuritis Treatment Trail (ONTT) (Optic Neuritis Study Group, 1991). Bestcorrected visual acuity, visual field, optic coherence tomography (OCT) devices, optic nerve MRI with a T2weighted image (T2WI) sequence with fat suppression, a T1-weighted image (T1WI) sequence with fat suppression and a gadolinium-enhanced T1 were performed in all patients. Cell-based assays to detect serum AQP4-Ab and MOG-Ab were performed for all patients. Lumbar

show abstract

COVID-19-associated optic neuritis – A case series and review of literature

Cited by 42 publications

References 22 publications

Effect and mechanism of quercetin or quercetin‐containing formulas against COVID‐19: From bench to bedside

Effect and mechanism of quercetin or quercetin‐containing formulas against COVID‐19: From bench to bedside

Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches

Clinical features and prognosis in the first episode of optic neuritis with COVID‐19

Contact Info

Product

Resources

About